Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib + Checkpoint Inhibitors in Solid Tumors
NCT03511222Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vorolanib in solid tumor, hepatocellular carcinoma (HCC), gastric cancer (GC) and 2 more (3 arms), sponsored by Washington University School of Medicine. Primary endpoint: Recommended Phase II Dose at 13 months. Started Sep 2018; status: terminated.
02
Drugs
vorolanib
03
Conditions
solid tumorhepatocellular carcinoma (HCC)gastric cancer (GC)gastroesophageal junction adenocarcinomasmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03511222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03511222.